Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
self-assembling Lassa fever vaccine
- Development stage
- Preclinical
- Lead developer
- Vaccine and Immunotherapy Center
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
The self-assembling Lassa fever vaccine is a preclinical-stage vaccine candidate developed by the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital. The vaccine utilizes a self-assembling platform designed to present Lassa virus antigens in a particulate or nanoparticle format. This approach is intended to enhance the immune response by mimicking the physical structure of a virus, potentially leading to more robust and durable protection against Lassa fever, a viral hemorrhagic fever endemic to parts of West Africa. The program is currently in the preclinical efficacy and safety stages of development.
- Other names
- Self Assembling Vaccine (Lassa Fever)self-assembling vaccine-Lassa Fever
02
Targets
StreptavidinLassa virus antigens
Beyond the preview
Go deeper on self-assembling Lassa fever vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on self-assembling Lassa fever vaccine.